相关实验视频

Updated: May 21, 2025

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

基于附属体的HER2前药对HER2阳性癌细胞显示有条件的细胞毒性作用

Cornelia Westerberg¹, Anna Mestre Borras¹, Stefan Ståhl¹

¹Department of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm, Sweden.

Biochemical and biophysical research communications

|March 21, 2025

概括

这项研究引入了一种基于亲体的前药物策略,以改善癌症治疗中的瘤选择性. 通过使用瘤相关蛋白酶进行激活,这种方法旨在减少瘤外毒性.

科学领域:

生物技术是生物技术.
分子生物学分子生物学
癌症治疗方法癌症治疗方法

背景情况:

治疗性亲和蛋白质通过结合与疾病相关的分子,通常是瘤细胞上过度表达的受体,提供向癌症治疗.
在点上,瘤外的毒性是一个重大的挑战,因为在健康组织中存在点分子.
增强瘤选择性对于最小化向癌症治疗中的副作用至关重要.

研究的目的:

为增强瘤选择性开发和验证基于亲体的前药概念.
利用瘤相关蛋白酶在瘤部位选择性激活前药物.
在临床前模型中评估HER2特异性附带体前药物的疗效和安全性.

主要方法:

设计和生产具有独特蛋白质酶基质的HER2特异性附体前体候选药物.
评估由瘤相关蛋白酶和随后的HER2结合激活前药物.
将主要前药物候选物与细胞毒剂DM1结合,用于在HER2阳性癌细胞中的体外细胞毒性评估.

主要成果:

成功设计和表征HER2特异性附体前体药物.
通过相应的瘤相关蛋白酶对前药物进行选择性激活.
这种DM1结合前药物表现出强烈的,依赖HER2的细胞毒性,当前药物激活不存在时,毒性显著降低.

结论:

由瘤相关蛋白酶激活的依附体基前药物代表了增强瘤选择性的可行策略.
这种方法有望在向癌症治疗中最大限度地降低瘤外毒性.
进一步开发蛋白酶激活前期药物可能会导致更安全,更有效的癌症治疗.

关键词:

附属体附属体附属体附属体抗体与药物的结合物.有条件的激活方式一个药物产品.有选择性的瘤向向.瘤蛋白酶是一种瘤蛋白酶.

更多相关视频

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...